Pharmaceuticals

Negative Pressure Wound Therapy Market Size, Share & Trends Analysis Report, By Product Type (Conventional NPWT Devices, Disposable NPWT Devices, NPWT Accessories), By Wound Type (Burns and Surgical Open Wounds, Pressure Ulcers, Diabetic Foot Ulcers, Venous Leg Ulcers, Traumatic Wound), By End User (Home Care Settings, Hospitals, Others), By Region, Forecasts, 2024-2031

The Negative Pressure Wound Therapy Market Size was valued at USD 2.47 Bn in 2023 and is predicted to reach USD 4.11 Bn by 2031 at a 6.8% CAGR during the forecast period for 2024-2031. Negative pressure wound therapy uses controlled negative pressure to remove extra fluid from open wounds through a sealed or foam dressing that is linked to a collection container. It is a noninvasive method. A number of factors are driving the expansion of the ...

Report ID: 2838  |  

Delivery: Immediate  |  

Published: October 2024   |  

No. of Pages: 167

The Retinoic Acid Pathway Therapeutics Market Size, Share & Trends Analysis Distribution by Product Type (Retinoic Acid Receptor Agonists (RAR Agonists), Retinoid X Receptor Agonists (RXR Agonists), RAR and RXR Dual Agonists, Others (Novel/Next-Generation Retinoic Acid Derivatives)), Application, Route of Administration, Distribution Channel, End-user and Segment Forecasts, 2024-2031

The Retinoic Acid Pathway Therapeutics Market Size is predicted to grow at an 7.4% CAGR during the forecast period for 2024-2031. The retinoic acid pathway therapeutics market is a fast-emerging field dealing with the discovery and application of retinoic acid, which is a vitamin A metabolite, in a variety of medical therapies. RA plays an important role in biologic processes, such as cell differentiation, growth regulation, and apoptosis. The...

Report ID: 2816  |  

Delivery: Immediate  |  

Published: October 2024   |  

No. of Pages: 170

Synthetic Blood Substitute Market, Share & Trends Analysis Report, By Application (Cardiovascular Diseases, Malignant Neoplasma, Injuries, Neonatal Conditions, Organ Transplant, Maternal Condition), By End-use, By Product, By Source, By Component, By Configuration, By Region, and Segment Forecasts, 2024-2031

The Synthetic Blood Substitute Market Size is valued at USD 7.26 Bn in 2023 and is predicted to reach USD 20.75 Bn by the year 2031 at an 14.3% CAGR during the forecast period for 2024-2031. The global synthetic blood substitute industry is rapidly evolving, focusing on the development of artificial blood products to overcome the limitations of traditional blood transfusions. These substitutes aim to address issues such as blood type compatibi...

Report ID: 2798  |  

Delivery: Immediate  |  

Published: September 2024   |  

No. of Pages: 170

Catastrophic Antiphospholipid Syndrome Market Size, Share & Trends Analysis Report, By Treatment (Anticoagulants, Immunosuppressive Therapy, Plasma Exchange Therapy, Intravenous Immunoglobulin (IVIG) and Others), By End-use (Hospitals, Clinics, Others), By Region, Forecasts, 2024-2031

The Catastrophic Antiphospholipid Syndrome Market Size was valued at USD 4.38 Bn in 2023 and is predicted to reach USD 9.34 Bn by 2031 at a 10.2% CAGR during the forecast period for 2024-2031. Catastrophic antiphospholipid syndrome refers to an uncommon immunological condition marked by persistent antiphospholipid antigens, chronic arterial or venous embolism, and reproductive mortality. It is more common in women and may develop as eithe...

Report ID: 2786  |  

Delivery: Immediate  |  

Published: September 2024   |  

No. of Pages: 165

Longevity and Anti-Senescence Therapy Market Size, Share & Trends Analysis Report By Therapy (Senolytic Drug Therapy, Gene Therapy, Cell Therapy, Mitochondrial Therapy, Immunotherapy, Others), By Application, By Region, And By Segment Forecasts, 2024-2031

The Longevity and Anti-Senescence Therapy Market Size is valued at USD 2,736.43 million in 2023 and is predicted to reach USD 4,121.54 million by the year 2030 at a 6.8 % CAGR during the forecast period for 2024-2030. Longevity is an effective approach focuses on the extension of health span by slowing the rate of aging. This approach is considered as the most efficient way to combat various aging-related chronic illnesses and disabling condit...

Report ID: 1354  |  

Delivery: Immediate  |  

Published: September 2024   |  

No. of Pages: 185

Oligonucleotide Delivery System Market Size, Share & Trends Analysis Distribution by Delivery System (Conjugation-Based Delivery Systems (GALNAc Conjugation, Ligand Conjugation, Antibody Conjugation, Targeting Moiety Conjugation), Nanoparticle-Based Delivery Systems (Lipid Nanoparticles (LNPs), Peptide Nanoparticles), Viral Vector-Based Delivery Systems (Adeno-associated Virus (AAV) Vectors, AAV9, Lentiviral Vectors, Others), Exosome-Based Delivery Systems, Liposomes, Others), Disease Indication and Segment Forecasts, 2024-2031

The Oligonucleotide Delivery System Market is predicted to grow at an 12.4% CAGR during the forecast period for 2024-2031. The delivery system of an oligonucleotide refers to the method and technologies applied for transferring oligonucleotides into cells where they could exert their therapeutic effects. Oligonucleotides, due to their size and chemical properties, face the challenge of penetration through the biological barriers to enter targe...

Report ID: 2779  |  

Delivery: Immediate  |  

Published: September 2024   |  

No. of Pages: 165

Lipid-Based Drug Delivery Systems Market Size, Share & Trends Analysis Distribution by Type of Lipid-Based System (Liposomes, Solid Lipid Nanoparticles (SLNs), Nanostructured Lipid Carriers (NLCs), Lipid Nanoparticles (LNPs), Micelles, Lipid-Polymer Hybrid Systems), Application, Route of Administration, Formulation and Segment Forecasts, 2024-2031

The Lipid-Based Drug Delivery Systems Market Size is predicted to grow with a an CAGR of 11.9% during the forecast period for 2024-2031. Lipid-based drug delivery systems (LBDDS) are intended to increase the delivery and efficacy of drugs that are poorly soluble in water. These systems employ lipids as carriers to promote drug bioavailability, resulting in greater absorption in the body. LBDDS are employed in a variety of pharmaceutical applic...

Report ID: 2764  |  

Delivery: Immediate  |  

Published: September 2024   |  

No. of Pages: 180

Bioactive Formulation for Functional F&B Market, Share & Trends Analysis Report, By Ingredient Type (Prebiotics, Probiotics, Adaptogens, Polyphenols, Omega-3 Fatty Acids, Antioxidants), By Formulation Technology (Encapsulation, Microemulsions, Liposomal Delivery), By Application, By Region, and Segment Forecasts, 2024-2031

The Bioactive Formulation for Functional F&B Market is predicted to grow at an 8.31% CAGR during the forecast period for 2024-2031. Bioactive formulations in functional food and beverages (F&B) utilize biologically active compounds that provide health benefits beyond basic nutrition. These formulations typically include ingredients such as polyphenols, prebiotics, probiotics, vitamins, peptides, and dietary fibers, which are targeted at...

Report ID: 2736  |  

Delivery: Immediate  |  

Published: September 2024   |  

No. of Pages: 180

Non-Sterile Outsourcing Market, Share & Trends Analysis Report, By Dosage form (Oral, Ear & Eye, Nasal, Topical, Parenteral), By Application (Human Medication, Nutraceuticals, Cosmetics, Medical Devices, Veterinary Health), By Region, and Segment Forecasts, 2024-2031

The Non-Sterile Outsourcing Market Size is valued at USD 7.50 Bn in 2023 and is predicted to reach USD 10.81 Bn by the year 2031 at an 4.8% CAGR during the forecast period for 2024-2031. A compounded medication product can be either non-sterile or sterile and contains one or more active ingredients. While it is possible to manufacture compounded sterile products internally, an alternative is to contract with a 503B outsourcing facility outside...

Report ID: 2740  |  

Delivery: Immediate  |  

Published: September 2024   |  

No. of Pages: 178

GMP Biologics Market, Share & Trends Analysis Report, By Type (Monoclonal Antibodies, Polyclonal Antibody), By Application (Hospitals, Clinics, Others), By Region, and Segment Forecasts, 2024-2031

The GMP Biologics Market Size is valued at USD 52.3 Bn in 2023 and is predicted to reach USD 153.9 Bn by the year 2031 at an 14.6% CAGR during the forecast period for 2024-2031. The term "Good Manufacturing Practice" (GMP) Biologics describes the manufacture of biologic pharmaceuticals by strict legal requirements intended to guarantee the effectiveness, safety, and quality of the final product. The World Health Organization (WHO) and other or...

Report ID: 2715  |  

Delivery: Immediate  |  

Published: August 2024   |  

No. of Pages: 165